Bisrat G Debeb

Has grant

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

The role of NDRG1 driven stemness in aggressive breast tumors

Open Date: 2023-03-01

Close Date: 2024-08-31

Grant: Close

Novel mechanisms of brain metastasis in aggressive breast cancers

Open Date: 2020-01-01

Close Date: 2024-12-31

Articles (6)

The MAPK pathway can drive resistance in highly aggressive breast cancers. Our previous work showed that the MEK inhibitor (MEKi) AZD6244 (selumetinib) prevented lung metastasis in a breast cancer xenograft model. In clinical studies, MEKis as single agents have had only modest activity against solid tumors due to the onset of resistance. Using synthetic lethality siRNA screening, we identified myeloid cell leukemia-1 (MCL-1) as a potential contributor to AZD6244 resistance. We hypothesized that MCL-1 promotes MEKi resistance in highly aggressive breast cancers and that MCL-1 inhibition overcomes AZD6244 resistance. We established two AZD6244-resistant cell lines: MDA-MB-231-R (triple-negative breast cancer) and SUM149-R (triple-negative inflammatory breast cancer). These resistant cells were characterized with respect to different parameters, and a combination of an MCL-1 inhibitor (MCL-1i) together with an MEKi was evaluated in vitro and in vivo to overcome the acquired resistance. Compared with their respective parental cells, MDA-MB-231-R and SUM149-R cells showed increased proliferation, colony formation, stemness, anchorage-independent growth, and MCL-1 expression levels. MCL-1 knockdown in resistant cells decreased cell proliferation and colony formation, increased apoptosis, and was associated with high expression of the proapoptotic proteins PUMA, NOXA, BAK, and BAX. MEKi resistance was overcome when resistant cells were treated with MCL-1i and MEKi combined. In an in vivo mouse model, inhibition of MCL-1 restored sensitivity to AZD6244. Our results suggest that MCL-1 is a driver of MEKi resistance and that combining an MCL-1i with an MEKi warrants further investigation in triple-negative and triple-negative inflammatory breast cancer.

Year:

2025

Fig. S3 CTB assay showing the effect of combination of drugs on SUM149-R cells. The SUM149-R cells showed a decrease in viability after treatment with the constant doses of AZD5991 (0.5, and 1µM) followed by the different doses of AZD6244.

Year:

2025

Fig. S2 Venn diagram of the number of significant siRNAs identified with a 5% false discovery rate using different normalization methods (Z-score, b-score, and regional scaling) for comparison between untreated and treated samples.

Year:

2025

The MAPK pathway can drive resistance in highly aggressive breast cancers. Our previous work showed that the MEK inhibitor (MEKi) AZD6244 (selumetinib) prevented lung metastasis in a breast cancer xenograft model. In clinical studies, MEKis as single agents have had only modest activity against solid tumors due to the onset of resistance. Using synthetic lethality siRNA screening, we identified myeloid cell leukemia-1 ( MCL- 1 ) as a potential contributor to AZD6244 resistance. We hypothesized that MCL-1 promotes MEKi resistance in highly aggressive breast cancers and that MCL- 1 inhibition overcomes AZD6244 resistance. We established two AZD6244-resistant cell lines: MDA-MB-231-R (triple-negative breast cancer) and SUM149-R (triple-negative inflammatory breast cancer). These resistant cells were characterized with respect to different parameters, and a combination of an MCL- 1 inhibitor ( MCL- 1 i) together with an MEKi was evaluated in vitro and in vivo to overcome the acquired resistance. Compared with their respective parental cells, MDA-MB-231-R and SUM149-R cells showed increased proliferation, colony formation, stemness, anchorage-independent growth, and MCL-1 expression levels. MCL-1 knockdown in resistant cells decreased cell proliferation and colony formation, increased apoptosis, and was associated with high expression of the proapoptotic proteins PUMA, NOXA, BAK, and BAX. MEKi resistance was overcome when resistant cells were treated with MCL-1 i and MEKi combined. In an in vivo mouse model, inhibition of MCL-1 restored sensitivity to AZD6244. Our results suggest that MCL-1 is a driver of MEKi resistance and that combining an MCL-1 i with an MEKi warrants further investigation in triple-negative and triple-negative inflammatory breast cancer.

Year:

2025

Fig. S4 Effect of combination of drugs on SUM149-R cells. The clonogenic assay shows a significant dose-dependent decrease in the colony formation capability of SUM149-R cells after treatment with the combination of MEKK inhibitor AZD6244 and MCL-1 inhibitor S63845 at the same time.

Year:

2025

Purpose Inhibiting HMG-CoA reductase with simvastatin prevents breast cancer metastases in preclinical models and radiosensitizes monolayer and stem-like IBC cell lines in vitro . Given the extensive use of simvastatin worldwide and its expected penetration into the brain, we examined whether regulating cholesterol with simvastatin affected IBC3 HER2+ brain metastases. Methods and Materials Breast cancer cell lines KPL4 and MDA-IBC3 were examined in vitro for DNA repair after radiation with or without statin treatment. Brain metastasis endpoints were examined in the MDA-IBC3 brain metastasis model after ex vivo exposure to lipoproteins and after tail vein injections with and without whole-brain radiotherapy (WBR) and oral statin exposure. Results Ex vivo preculture of MDA-IBC3 cells with very low-density lipoprotein (vLDL) enhanced the growth of colonized lesions in the brain in vivo compared with control or high-density lipoprotein (HDL), and concurrent oral simvastatin/ WBR reduced the incidence of micrometastatic lesions evaluated 10 days after WBR. However, statin, with or without WBR, did not reduce the incidence, burden, or number of macrometastatic brain lesions evaluated 5 weeks after WBR. Conclusions Although a role for cholesterol biosynthesis is demonstrated in DNA repair and response to whole brain radiation in this model, durable in vivo efficacy of concurrent whole brain irradiation and oral statin was not demonstrated.

Year:

2024

Collaborators (11)

Naoto Ueno

Professor of Medicine

University of Hawai'i Cancer Center

UNITED STATES
View details

Lajos Pusztai

Yale University

UNITED STATES
View details

Jay Paul Reddy

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Varsha Gandhi

Professor & Chair ad interim

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Richard Amos

University College London

UNITED KINGDOM
View details

Stephanie M. Cologna

Associate Professor

University of Chicago

UNITED STATES
View details

Bora Lim

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Geoffrey Bartholomeusz

Associate Professor, Director Target Identification and Validation Program

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Shane Stecklein

University of Kansas Cancer Center

UNITED STATES
View details

Xiaoding Hu

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Wendy Woodward

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details